Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit

  • Celltrion completes first step of developing an antiviral treatment to fight COVID-19 and hopes to begin human clinical trials in the third quarter of 2020
  • Celltrion aims to launch the rapid self-testing diagnostic kit for COVID-19 this summer: the kit is designed to provide results within 15-20 min of self-testing
  • Leveraging its world-class expertise in biologics, Celltrion Group remains committed to supporting patients and healthcare systems throughout the pandemic

INCHEON, South Korea I March 23, 2020 I Celltrion Group today announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic. As part of its emergency preparedness plan to address the outbreak, which has infected over 200,000 people worldwide,1,2 Celltrion has successfully completed the first step of developing an antiviral treatment to fight COVID-19 and aims to launch a rapid self-testing diagnostic kit that could provide results within 15-20 minutes.

Celltrion has been selected as a preferred developer for a monoclonal antibody project to treat and prevent COVID-19 by the Korea Centers for Disease Control (KCDC). Korea was one of the first countries to be affected by the global pandemic.3 Celltrion has identified the library of antibodies sourced from the blood of recovered patients in Korea, which are thought to be involved in neutralising the virus and may contribute to recovery from COVID-19. These antibodies are undergoing further screening processes to identify those that are most effective in neutralising the virus causing COVID-19. Once identified these will form the basis of the antiviral treatment to be tested through pre-clinical and clinical trials around the world in the third quarter of 2020.

Furthermore, Celltrion plans to develop a ‘super antibody’ that can attach and neutralise all kinds of coronavirus related strains, such as those causing COVID-19 and SARS, enabling further protection against unforeseen or unexpected mutations. Celltrion hopes the ‘super antibody’ candidate could contribute towards preparedness for potential future pandemic situations.

Alongside therapeutic antibody development, Celltrion aims to launch a rapid self-testing diagnostic kit in the summer of this year. The kit will focus on the gene that encodes the surface spike (S) protein; an essential glycoprotein for viral entry into human host cells. The kit is designed to show results within 15-20 minutes, with optimised sensitivity, specificity and improved accuracy features. Once it has gained a CE mark, the rapid self-testing diagnostic kit will become available throughout Europe through Celltrion Healthcare. Celltrion plans to apply for device authorisation from the FDA in the US and other regulatory authorities after acquiring relevant data.

Ki-Sung Kwon, Head of R&D Division at Celltrion said, “Our COVID-19 antiviral treatment is designed to train the immune system to make antibodies that recognise and block the spike protein that the virus uses to enter human cells. Antibodies that bond to the COVID-19 antigen will also be used to develop a diagnostic kit. We implemented an emergency preparedness plan at the very start of the COVID-19 outbreak leveraging our unique antibody discovery, development and manufacturing technologies. We remain dedicated to supporting healthcare systems across the world and innovating to support patients throughout this pandemic.”

- ENDS -

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

About COVID-194

Coronaviruses (CoV) are a family of viruses that lead to illnesses from the common cold to severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Novel coronavirus SARS-CoV-2 is responsible for the disease COVID-19, this new strain, discovered in 2019, is behind the ongoing pandemic outbreak.

Common signs of COVID-19 include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure and ultimately death.

Please find up to date information about the outbreak via the World Health Organization at https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

References

1 Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). John Hopkins University. Available at: https://coronavirus.jhu.edu/map.html Last accessed: March 2020

2 Novel Coronavirus (COVID-19) Situation. World Health Organization. Available at: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd Last accessed: March 2020

3 Novel Coronavirus – Republic of Korea (ex-China). World Health Organization. Available at: https://www.who.int/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-china/en/ Last accessed: March 2020

4 Coronavirus. World Health Organization. Available at: https://www.who.int/health-topics/coronavirus Last accessed: March 2020

SOURCE: Celltrion

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top